Uploaded July 2026 | Updated September 2026, 2 weeks ago
Voyager Therapeutics reported that a single IV dose of its investigational gene therapy, VY1706, reduced tau protein in the brain by up to 75% in non-human primates, with the effect lasting six months. The therapy crosses the blood-brain barrier using the ALPL receptor and works by reducing tau production at its source, offering a potential new approach to treating Alzheimer's disease.
Full Episode on YouTube, Spotify and Apple Podcast. Link in the comment.
#LongevityTechnologyUnlocked #LongevityPodcast #Alzheimers #VoyagerTherapeutics #GeneTherapy #BrainHealth
Voyager Therapeutics reported that a single IV dose of its investigational gene therapy, VY1706, reduced tau protein in the brain by up to 75% in non-human primates, with the effect lasting six months. The therapy crosses the blood-brain barrier using the ALPL receptor and works by reducing tau production at its source, offering a potential new approach to treating Alzheimer's disease.
Full Episode on YouTube, Spotify and Apple Podcast. Link in the comment.
#LongevityTechnologyUnlocked #LongevityPodcast #Alzheimers #VoyagerTherapeutics #GeneTherapy #BrainHealth
